TICKERNERD
Menu
BNGOBNGOHealthcare · Medical Instruments & Supplies

BNGO Stock Forecast: Bionano Genomics, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$1.35
−6.60% on the day

The 2 Wall Street analysts covering Bionano Genomics, Inc. hold a median 12-month price target of $5 — +271.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 10 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$16.9M
Ticker Nerd rank
77 / 100
Median analyst target
$5.00
Analysts covering
2
Revenue$8.2M+21.4% y/y
Operating income−$7.2M
Net income−$7.4M
Free cash flow−$4.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.2%
1M
+10.2%
YTD
−12.1%
1Y
−31.0%
From 52W high
−36.6%
From 52W low
+26.9%
$1.06
$2.12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BNGO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bionano Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Oct 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
90
Size
89
Growth
71
Revisions
70
Quality
67
Issuance
58
Volatility
42
Momentum
34
Value
23

Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (23): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BNGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BNGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26BNGOHigh $6.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $4.00Median $5.00High $6.00

The green dot is the last close — the median target sits +271.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
13 Apr 2026HC Wainwright & Co.MaintainsBuy$7.00 → $6.00
13 Apr 2026HC Wainwright & Co.MaintainsBuy—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
18 Aug 2025HC Wainwright & Co.MaintainsBuy—
20 May 2025Maxim GroupUpgradeBuy—
9 Apr 2025HC Wainwright & Co.InitiatesBuy—
2 Apr 2025ScotiabankMaintainsSector Perform—
15 Nov 2024Ladenburg ThalmannDowngradeNeutral—
10 Sept 2024BTIGDowngradeNeutral—
28 Aug 2024ScotiabankDowngradeSector Perform$6.00 → $1.00
16 May 2024BTIGMaintainsBuy—
7 Mar 2024ScotiabankMaintainsSector Outperform—
13 Nov 2023Maxim GroupDowngradeHold—
10 Aug 2023BTIGMaintainsBuy—
9 June 2023BTIGMaintainsBuy—
25 May 2023EF HuttonInitiatesBuy$1.75
18 May 2023BTIGMaintainsBuy$3.00 → $2.00
24 Apr 2023BTIGMaintainsBuy—
10 Mar 2023BTIGMaintainsBuy—
6 Feb 2023OppenheimerMaintainsOutperform$12 → $9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BNGO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BNGO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Bionano Genomics, Inc. returned −31.0% against +20.5% for the S&P 500, dividends included.

BNGO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26BNGOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BNGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Bionano Genomics, Inc. (BNGO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
0.6×

Cheaper than 80% of US stocks

Price / book
0.5×

Cheaper than 83% of US stocks

EV / EBITDA
−0.6×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
21.4%

Higher than 70% of US stocks

Earnings growth (YoY)
21.4%

Higher than 59% of US stocks

Gross margin
52.8%

Higher than 65% of US stocks

Operating margin
−88.3%

Higher than 14% of US stocks

Net margin
−106.6%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−83.6%

Higher than 15% of US stocks

Return on assets
−32.6%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bionano Genomics, Inc. (BNGO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bionano Genomics, Inc. has a market value of $16.9M and an enterprise value of $13.7M.

  • Revenue in the twelve months to 30 June 2026: $30.2M. The latest quarter grew 21.4% year on year.

  • Net income over the same four quarters: −$32.2M, a −106.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.01.

  • Free cash flow in the twelve months to 30 June 2026: −$20.5M.

  • Shares outstanding: 11.8M.

  • Trailing P/E: 0.0×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Bionano Genomics, Inc. employs 95 people — $318K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Oct 2026

Data provided by Twelve Data

Peers

BNGO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BNGOBionano Genomics, Inc.$16.9M
77
FEMYFemasys, Inc.$16.8M
47
RVPRetractable Technologies, Inc.$19.9M
62
RGNTRegentis Biomaterials Ltd.$11.2M
8
CUPRCuprina Holdings (Cayman) Ltd.$10.0M
5
MLSSMilestone Scientific, Inc.$30.8M
87
LUCYInnovative Eyewear, Inc.$7.8M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bionano Genomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BNGO news & analysis

Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies

GlobeNewsWire · 23 Sept 2026positive

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, announced the expansion of optical genome mapping-based diagnostic testing for hematologic malignancies at Memorial Sloan Kettering Cancer Center, following approval from the New York State Department of Health.

Why it matters — This reflects broader adoption of Bionano's OGM technology at a major cancer center through regulatory approval, which could expand the reach of its testing services.

Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia

GlobeNewsWire · 14 Sept 2026positive

Bionano announced three new peer-reviewed studies from independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute. The studies demonstrate that optical genome mapping uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification in myelodysplastic syndromes, acute myeloid leukemia, and therapy-related myeloid neoplasms.

Why it matters — Independent peer-reviewed evidence of OGM's ability to detect clinically significant genomic alterations in hematologic cancers could support broader clinical adoption of Bionano's technology.

Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

GlobeNewsWire · 10 Sept 2026positive

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, announced that MolDX has issued a proposed Local Coverage Determination (LCD) for Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms. MolDX assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors.

Why it matters — A proposed Medicare LCD could move Bionano's genome-wide test toward reimbursement coverage, potentially broadening the commercial market for its technology.

Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping

GlobeNewsWire · 8 Sept 2026positive

Bionano Laboratories announced that the New York State Department of Health has granted approval allowing clinical use of optical genome mapping (OGM) based lab developed tests (LDTs). These tests will be available at University of Rochester Medicine for patients with suspected genetic disease, reproductive disorders, and hematologic malignancies.

Why it matters — This regulatory approval enables clinical deployment of Bionano's OGM-based tests, expanding their commercial reach into a state with stringent regulatory requirements.

Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 24 Aug 2026neutral

Bionano Genomics announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026.

Why it matters — BNGO watchers would care because the company's management will present and hold one-on-one meetings with investors at a major investment conference, providing visibility into the company.

FAQ

Frequently asked questions about BNGO stock

What is the BNGO stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Bionano Genomics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BNGO stock a buy right now?

Of the 2 analysts covering Bionano Genomics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bionano Genomics, Inc. 77 out of 100 across roughly 4,600 US stocks as at 10 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BNGO?

As at 10 Oct 2026, Bionano Genomics, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).

Will BNGO stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +271.7% from the last close, and Ticker Nerd's factor model ranks Bionano Genomics, Inc. 77 out of 100 as at 10 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BNGO stock forecast for 2030?

No analyst covering Bionano Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BNGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has BNGO stock performed over the past year?

Bionano Genomics, Inc. returned -31.0% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bionano Genomics, Inc. do?

Bionano Genomics Inc. is a life sciences instrumentation company focused on genome analysis.

What is the latest news on BNGO?

The most recent item we track (GlobeNewsWire, 23 Sept 2026): "Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies". Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, announced the expansion of optical genome mapping-based diagnostic testing for hematologic malignancies at Memorial Sloan Kettering Cancer Center, following approval from the New York State Department of Health.

Company

About Bionano Genomics, Inc.

Bionano Genomics Inc. is a life sciences instrumentation company focused on genome analysis. The company develops and commercializes optical genome mapping solutions, including the Saphyr and Stratys systems, along with consumables, sample-preparation kits, and software used to analyze structural variation and other genomic changes. Its platform is designed for researchers and clinicians working in basic, translational, and clinical research, supporting applications in cytogenetics, rare disease studies, reproductive health, prenatal genetics, and oncology research. Bionano Genomics also offers data analysis tools that help laboratories visualize, interpret, and report genomic findings across multiple platforms. Headquartered in San Diego, California and founded in 2003, Bionano Genomics serves customers in global research and clinical markets with an integrated workflow for genome mapping and interpretation.

CEO Dr. Albert A. Luderer Ph.D. · 95 employees · United States · https://bionano.com